摘要:
The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds of Formula (I) and Formula (II), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.
摘要:
The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.
摘要:
The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds of Formula (I) and Formula (II), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.
摘要:
The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.
Wherein Z is N or CR 1 , A 1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A 2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R 1 , R 2 , R a , R b , R c and R d are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -CONR 5 (CR 3 R 4 )n-, -NR 5 CONR 6 (CR 3 R 4 )n-, -(CR 3 R 4 ) m NR 5 CO- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R 3 and R 4 are each independently hydrogen, halogen, hydroxy etc., and R 5 and R 6 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or solvate thereof. The nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.
Wherein Z is N or CR 1 , A 1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A 2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R 1 , R 2 , R a , R b , R c and R d are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -CONR 5 (CR 3 R 4 )n-, -NR 5 CONR 6 (CR 3 R 4 )n-, -(CR 3 R 4 ) m NR 5 CO- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R 3 and R 4 are each independently hydrogen, halogen, hydroxy etc., and R 5 and R 6 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or solvate thereof. The nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.
摘要翻译:由下式表示的化合物:其中Z是N或CR1,A1是任选被取代的含氮芳族单环基团,任选被取代的含氮芳族稠合环状基团等,A2是芳族烃环状基团或 芳香族杂环基,各自任选具有取代基,R 1,R 2,R a,R b,R c和R d各自独立地为氢,羟基等,w为2或3,t为1或2,X为-CONR 5(CR 3 R 4) n - , - NR5CONR6(CR3R4)n - , - (CR3R4)mNR5CO-等,m为1至4的整数,n为0至4的整数,R3和R4各自独立地为氢,卤素,羟基等 并且R5和R6是氢或低级烷基,或其药学上可接受的盐或溶剂化物。 由式(I)表示的含氮杂环衍生物特异性结合NR 1 / NR 2 B的受体,并用作NR 2 B受体拮抗剂。